In IDH-mutated AML, the combination of the IDH inhibitors ivosidenib and enasidenib (see below) with intensive chemotherapy (“7 + 3” regimen, followed by high-dose cytarabine) was recently explored in a phase I study [70]. This evidence concerns the gene IDH2 and acute myeloid leukemia.